Rare viral infections in children receiving hemopoietic stem cell transplant

Castagnola, Elio; Faraci, Maura; Moroni, C.; Marco, Eddi Di; Cirillo, C.; Rabagliati, A. M.; Ricci, Roberto; Natalizia, A R; Fazio, Valeria; Morreale, Giuseppe; Granata, Claudio; Lanino, Edoardo; Dini, Giorgio; Haupt, Riccardo

doi:10.1038/bmt.2008.65

Cited by 5 publications

(2 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the data on the detection of HHV-7 in pityriasis rosea have been controversial [Kempf, 2002], recent studies reveal its causal role [Broccolo et al, 2005;Canpolat Kirac et al, 2009]. After allogeneic hematopoietic cell transplantation, HHV-7 has been reported as a cause of severe central nervous system disease [Castagnola et al, 2008]. In addition, HHV-7 was associated with severe GVHD and sepsis secondary to severe immunosuppression after transplantation from matched unrelated donors [Khanani et al, 2007].…”

Section: Clinical Symptomsmentioning

confidence: 99%

Hematopoietic cell transplantation and emerging viral infections

Chatzidimitriou¹,

Gavriilaki²,

Sakellari³

et al. 2010

Journal of Medical Virology

View full text Add to dashboard Cite

Viral infections remain important causes of morbidity and mortality in hematopoietic cell transplant recipients. More recent developments in preparative regimens and graft manipulations, as well as the control of well-recognized post-transplant infections by the introduction of prophylaxis and preemptive strategies, have influenced the timing and the epidemiology of infections. As new pathogens, such as human metapneumovirus (HMPV), human bocavirus, human coronaviruses HCoV-NL63 and HCoV-HKU1, human herpesviruses HHV-6 and HHV-7, and polyomaviruses, have emerged, it is fundamental to determine the significance of the newly discovered viruses and their role in the transplantation field. This article summarizes recent data on epidemiology and laboratory diagnosis of new pathogens, as well as clinical features and management of the associated infectious complications. J. Med. Virol. 82:528-538, 2010. (c) 2010 Wiley-Liss, Inc.

show abstract

Section: Clinical Symptomsmentioning

confidence: 99%

Hematopoietic cell transplantation and emerging viral infections

Chatzidimitriou¹,

Gavriilaki²,

Sakellari³

et al. 2010

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Adenovirus and rotavirus have been reported as important etiologic agents [12]. Viruses may cause mucosal damage, increasing patients' vulnerability to infection by intestinal bacteria, and hence these patients require close monitoring [13]. Norovirus can cause significant morbidity and even mortality in immunocompromised hosts, including solid organ transplant recipients [14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Norovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Incidence, Risk Factors, and Outcome

Robles

Cheuk

et al. 2012

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Norovirus infections are increasingly being recognized as important causes of diarrhea in hematopoietic stem cell transplantation (HSCT) recipients. This retrospective study aimed to evaluate the cumulative incidence, risk factors, and outcomes of norovirus infection in pediatric HSCT recipients. Among 55 patients age \21 years who underwent first HSCT between July 2007 and June 2011, 49 patients developed diarrhea and had stool tested for norovirus. Eight of these patients were found to be infected with norovirus. All were sporadic cases and manifested with nausea, vomiting, and diarrhea. The median age of these patients was 5.2 years (range, 0.5-18.5 years). Six were males. Seven patients underwent unrelated donor HSCT, and 1 patient underwent autologous cord blood HSCT. Two patients had norovirus infection before HSCT that persisted after transplantation. In the remaining 6 patients, norovirus developed at a median of 36.5 days posttransplantation (range, 5-517 days). The cumulative incidence of norovirus infection was 12.9% at 2 years posttransplantation. Risk factors for norovirus infection included the use of peripheral blood or cord blood as the stem cell source (P 5 .043) and administration of fludarabine (P 5 .002) and alemtuzumab (P 5 .011). The median time to viral clearance was 145 days (range, 13-263 days). Four-year survival was similar in norovirus-infected patients and noninfected patients (56.3% versus 58.3%).

show abstract